The 30th European Hematology Association (EHA) Congress (EHA 2025), held in Milan, Italy, from June 12-15, 2025, continued ...

The U.S. FDA’s green lighting of Omeros Corp.’s Yartemlea (narsoplimab) makes it the first approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...

As of Wednesday, December 24, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 5.52%, which has investors questioning if this is right time to sell.

In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

About 1 in 10 adults aged 70 or older may be eligible for anti-amyloid therapy, finds the first population-based study to use ...

Reviva Pharmaceuticals Holdings Inc. may be headed back to the clinic for another phase III study of brilaroxazine in treating schizophrenia. The U.S. FDA recommended the second study for the ...

A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver ...

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 23, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential ...

Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...

The patient, who died on December 14, was originally enrolled in a Phase III study in 2022 and transitioned into an extension phase in 2023.

NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an ...